Celularity Valuation Multiples

Celularity Overview

About Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Founded

2018

HQ

Employees

123

Website

celularity.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $54M

EBITDA: ($44M)

EV

$102M

Valuation Multiples

Multiples.vc

Start free trial

Celularity Financials

Celularity reported last fiscal year revenue of $54M and negative EBITDA of ($44M).

In the same fiscal year, Celularity generated $39M in gross profit, ($44M) in EBITDA losses, and had net loss of ($58M).

Celularity P&L

In the most recent fiscal year, Celularity reported revenue of $54M and EBITDA of ($44M).

Celularity expects next 12-month revenue of XXX and NTM EBITDA of XXX

Celularity Stock Performance

Celularity has current market cap of $36M, and enterprise value of $102M.

Celularity's stock price is $1.24.

Celularity Valuation Multiples

Celularity trades at 1.9x EV/Revenue multiple, and (2.3x) EV/EBITDA.

Celularity Financial Valuation Multiples

As of April 21, 2026, Celularity has market cap of $36M and EV of $102M.

Equity research analysts estimate Celularity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Celularity has a P/E ratio of (0.6x).

Celularity Margins & Growth Rates

Celularity's revenue in the last fiscal year grew by 138%.

Celularity's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.6M for the same period.

Celularity Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Celularity M&A Activity

Celularity acquired XXX companies to date.

Last acquisition by Celularity was on XXXXXXXX, XXXXX. Celularity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Celularity Investment Activity

Celularity invested in XXX companies to date.

Celularity made its latest investment on XXXXXXXX, XXXXX. Celularity invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).